FindTrial
Sign In

A study to evaluate the efficacy of selected homoeopathic medicines in the treatment of COVID-19 as an adjuvant therapy.

Adjuvant Homoeopathic Treatment, along with Standard Conventional Treatment in third and subsequent waves of COVID-19 in Delhi ââ?¬â?? A Prospective, Open label, Multicentric, Exploratory Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/02/040028
Enrollment
500
Registered
2022-02-04
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Homoeopathic Medicine: Subjects will receive Homoeopathic medicines based on their indicated symptoms. Medicines shall be prescribed in 30C potency, 4 pills of size 30, three times or f

Sponsors

Directorate of AYUSH Govt of NCT of Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Mild, moderate cases laboratory confirmed cases of COVID-19. Willing to give oral/ written informed consent Subjects of age > 18years

Exclusion criteria

Exclusion criteria: Patients with severe/ critical disease will be excluded from the study

Design outcomes

Primary

MeasureTime frame
The Outcome in Relation to Impact on Daily Living (ORIDL) scale, which ranges fromââ?¬â??4 to +4, will be used for patient assessment at each follow-upTimepoint: Baseline, 1week, 2 week—

Secondary

MeasureTime frame
Change in the Symptom severity. Average duration until disease recovery after testing positive/day of appearance of symptoms.Timepoint: 7days—

Countries

India

Contacts

Public ContactDr Anjali Miglani

Directorate of AYUSH, Government of NCT of Delhi

dranjalidwk@gmail.com9311500829

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026